lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Chief Executive Officer, Key Assets Europe. For services to Fostering. Rowan Edwin Crozier. Chief Executive Officer, C Brandauer & Co. For services to Manufacturing and Enterprise. Dr. Donald Murray Cruickshank. General Practitioner, Upper Deeside. For services to the Medical Profession and to the community of Braemar, Aberdeenshire. Diana Jane Andrews Cunningham. Peer Trainer, Sussex Recovery College. For services to Mental Health. Suzette Louise Davenport, QPM. Chair, National Driver Offending Retraining Scheme. For services to Road Safety. Jessica Miriam Bryson Davidson. Senior Clinical Forensic Charge Nurse. For services to Forensic Nursing and to Victim Support in Scotland. Donna Marie Dawber. News and Campaigns Manager, Merseyside Police. For services to Law and Order. Dr. Edward James Day. Clinical Reader in Addiction Psychiatry, University of Birmingham. For services to Vulnerable People. Shaun Andrew Day. Headteacher, The Unicorn School, Abingdon, Oxfordshire. For services to Education. Paula Rosemary Deas. Deputy Chief Executive, Coventry and Warwickshire Local Enterprise Partnership. For services to the community in the West Midlands. Keith Deller. For charitable services to the community in Suffolk. Jack Robert Clarke Deverson. Co-Founder and Managing Director, Evidence Based Education. For services to Education. Ruth Heather Devine. Route Panel Member, Institute for Apprenticeships and Technical Education. For services to Further Education and Apprenticeships. Deborah Heather Dixon (Deborah Williams). For services to the community in Poole, Dorset.
== History == Scientists in Japan began to collaborate as early as 1939 on the development of an electron microscope. Kenji Kazato and Kazuo Ito met while working at the Naval Central Institute in Tokyo during World War II. After the war, Kazato attracted Ito and a group of others to Mobara, Chiba Prefecture, Japan. This initial group developed a prototype magnetic field–type electron microscope called the DA-1, which was sold to Mitsubishi in 1947. Because of differences over the direction of this early company, Kazato and Ito chose to found a new organization. The Japan Electron Optics Laboratory Company, Limited (Nihon Denshi Kogaku Kenkyujo) was founded in 1949 by Kenji Kazato and Kazuo Ito in Mitaka, Tokyo. It produced its first commercial model transmission electron microscope, the JEM-1, a year later. Overseas sales began in 1956 with the sale of a system to France. The company's strengths were the customization of orders to fit customer requests, and the provision of strong customer support. In 1961, the company was renamed JEOL, Limited. Its first overseas subsidiary, JEOL Company (USA) Inc., was established in 1962 and headquartered in Peabody, MA. JEOL was listed on the Second Section of the Tokyo Stock Exchange by 1962, and on the First Section of the Tokyo Stock Exchange by 1966. The company expanded from electron microscopy to nuclear magnetic resonance (NMR), releasing the first NMR system in Japan, the JNM-1, in 1956. They produced their first mass spectrometer in 1963, and their first scanning electron microscope in 1966.
Armored truck driver Box truck driver Car carrier driver Dump truck driver Flatbed truck driver Garbage truck driver Hopper trailer driver Logging truck driver Lowboy trailer driver Oversize load operator Refrigerated truck driver Tank truck driver Tow truck driver
Humanitarian daily rations are American rations supplied to civilians and other non-military personnel in humanitarian crises. The Unitized Group Ration is an American group ration designed to feed groups of personnel. They are divided into four types and can be fully prepared and heated within less than one hour. While most of them are not intended to be eaten in the field, the Unitized Group Ration – Express type can be prepared and eaten in the field.
with equality if and only if the two triangles are similar. The hinge theorem or open-mouth theorem states that if two sides of one triangle are congruent to two sides of another triangle, and the included angle of the first is larger than the included angle of the second, then the third side of the first triangle is longer than the third side of the second triangle. That is, in triangles ABC and DEF with sides a, b, c, and d, e, f respectively (with a opposite A etc.), if a = d and b = e and angle C > angle F, then
Sources: en.wikipedia.org
=== Diver's telephone === The communications equipment is relatively straightforward and may be of the two-wire or four-wire type. Two wire systems use the same wires for surface to diver and diver to surface messages, whereas four wire systems allow the diver's messages and the surface operator's messages to use separate wire pairs. In a two wire system the standard arrangement for diver communications is to have the diver's side normally on, so that the surface team can hear anything from the diver at all times except when the surface is sending a message. In a four-wire system the diver's side is always on, even when the surface operator is talking. This is considered an important safety feature, as the surface team can monitor the diver's breathing sounds, which can give early warning of problems developing, and confirms that the diver is alive. Heliox divers may need a decoder system (unscrambler) which reduces the frequency of the sound to make it more intelligible.
== Tandem accelerators == Two, tandem accelerators at this facility accelerate energies up to 3 million volts (3 MeV). The function of these accelerators is to measure scarce, (cosmogenic) isotopes such as aluminium-26, beryllium-10, iodine-129 and the aforementioned carbon-14. In other words, the accelerators are used for measuring rare isotopes that are produced within earth materials, such as rocks or soil, in Earth's atmosphere, and in extraterrestrial objects such as meteorites. These are cosmogenic isotopes, produced from interaction with cosmic rays.
== Measuring vapor == Since it is in the gas phase, the amount of vapor present is quantified by the partial pressure of the gas. Also, vapors obey the barometric formula in a gravitational field, just as conventional atmospheric gases do.
ADPRase is a dimer of two identical monomers, each of which contain 209 amino acids. The two monomers are folded into two distinct structural domains and with two equivalent catalytic sites. The C-terminal domain consists of the Nudix sequence mentioned above and the N-terminal domain is primarily involved in dimer stabilization. As noted earlier, the Nudix fold is the catalytic part of the enzyme, but both domains are involved in the active site and they both help with the attachment and coordination of H2O, Mg2+, and the ADP-ribose substrate.
Sources: en.wikipedia.org
Rett syndrome and fragile X syndrome (FXS) are single gene disorders related to autism with overlapping symptoms that include deficient neurological development, impaired language and communication, difficulties in social interactions, and stereotyped hand gestures. It is not uncommon for a patient to be diagnosed with both autism and Rett syndrome or FXS. Epigenetic regulatory mechanisms play the central role in pathogenesis of these two disorders. Genomic imprinting may also contribute to the development of autism. Genomic imprinting is another example of epigenetic regulation of gene expression. In this instance, the epigenetic modification(s) causes the offspring to express the maternal copy of a gene or the paternal copy of a gene, but not both. The imprinted gene is silenced through epigenetic mechanisms. Candidate genes and susceptibility alleles for autism are identified using a combination of techniques, including genome-wide and targeted analyses of allele sharing in sib-pairs, using association studies and transmission disequilibrium testing (TDT) of functional or positional candidate genes and examination of novel and recurrent cytogenetic aberrations. Results from numerous studies have identified several genomic regions known to be subject to imprinting, candidate genes, and gene-environment interactions. Particularly, chromosomes 15q and 7q appear to be epigenetic hotspots in contributing to autism. Also, genes on the X chromosome may play an important role, as in Rett syndrome.
His first tournament brought immediate reward. Colombia went through the group stage of the 1987 Copa América unbeaten, lost 2–1 to Chile in the semi-final, then beat the hosts Argentina 2–1 at the Monumental on 11 July through Gabriel Jaime Gómez and John Jairo Galeano, Claudio Caniggia replying late before 15,000 spectators. Arnoldo Iguarán finished as the tournament's leading scorer with four goals. The revival coincided with an influx of narcotics money into the domestic game. Atlético Nacional, funded through the Medellín Cartel and its leader Pablo Escobar, retained Colombian internationals who would otherwise have moved abroad and recruited foreign players the league could not previously afford; Maturana, who managed the club from 1987 to 1990, later acknowledged that "the introduction of drug money into soccer allowed us to bring in great foreign players. It also kept our best players from leaving. Our level of play took off." On 31 May 1989 Nacional, fielding Higuita, Andrés Escobar, Leonel Álvarez and Albeiro Usuriaga, beat Olimpia 5–4 on penalties at El Campín to become the first Colombian club to win the Copa Libertadores, supplying Maturana with a ready-made international spine. Colombia were eliminated in the group stage of the 1989 Copa América in Brazil, a 1–0 loss to Paraguay proving decisive despite a goalless draw with the eventual champions. The World Cup qualifiers opened a fortnight later.
== Function == The protein encoded by this gene is a member of the immunophilin protein family, which play a role in immunoregulation and basic cellular processes involving protein folding and trafficking. This encoded protein is a cis-trans prolyl isomerase that binds to the immunosuppressants FK506 and rapamycin. It has high structural and functional similarity to FK506-binding protein 1A (FKBP1A), but unlike FKBP1A, this protein does not have immunosuppressant activity when complexed with FK506. It interacts with interferon regulatory factor-4 and plays an important role in immunoregulatory gene expression in B and T lymphocytes. This encoded protein is known to associate with phytanoyl-CoA alpha-hydroxylase. It can also associate with two heat shock proteins (hsp90 and hsp70) and thus may play a role in the intracellular trafficking of hetero-oligomeric forms of the steroid hormone receptors. This protein correlates strongly with adeno-associated virus type 2 vectors (AAV) resulting in a significant increase in AAV-mediated transgene expression in human cell lines. Thus this encoded protein is thought to have important implications for the optimal use of AAV vectors in human gene therapy.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.